Over the past several years, there has been a steady rise in new biologic drugs coming onto the market for the treatment of chronic conditions such as multiple sclerosis, rheumatoid arthritis and autoimmune diseases. This trend is likely to continue in the future, with the IMS Institute for Healthcare Informatics predicting that the market for biologics will grow to $221 billion by 2017. Along with this new class of drugs comes a corresponding increase in selfadministration systems, which offer patients who must repeatedly self-dose the freedom to do so outside of the doctor’s office or clinic. The following article by Mike Schäfers, Vice President of Global Product Management and Marketing Operations at West Pharmaceutical Services, highlights the quality of design in pharmaceutical manufacturing.